Shield Therapeutics plc

Company Profile

Company website
Sector
Pharmaceuticals & Biotechnology (Pharmaceuticals)
Description

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

Investor Access

08 Sep
Event information

Management will hold a presentation for Investors through the digital platform, Investor Meet Company, on Thursday 8th September 2022 at 14:00 relating to the interim results for the six months ended 30 June 2022.  Investors can sign up to Investor Meet Company for free, by clicking here:

Venue
Online
Time
Thursday 8th September 2022 at 14:00
Financial Calendar
 Event  Date
Year End 31 December
Half  Year End 30 June
Preliminary Results* May
Interim Results* September
AGM* June

* Months based on previous announcements of this kind